No, Fasting C-Peptide and Fasting Insulin Do Not Reveal the Same Values
Fasting C-peptide and fasting insulin measurements are distinct biomarkers that reflect different aspects of insulin physiology and will not yield the same numerical values. While both are secreted in equimolar amounts by pancreatic beta cells, they differ fundamentally in their metabolism, clearance rates, and measurement units, making direct value comparison impossible.
Why the Values Differ
Metabolic and Clearance Differences
C-peptide and insulin follow completely different metabolic pathways after secretion:
- Insulin undergoes first-pass hepatic extraction: Approximately 50-80% of insulin is cleared by the liver on its first pass, while C-peptide largely bypasses hepatic metabolism 1
- C-peptide has a longer half-life: This results in higher circulating concentrations relative to insulin 1
- Renal clearance predominates for C-peptide: Unlike insulin's hepatic clearance, C-peptide is primarily cleared by the kidneys 1
The C-peptide/insulin molar ratio typically ranges from 5:1 to 15:1 in healthy individuals, demonstrating the substantial difference in their circulating levels 2. This ratio can be even more disparate in certain conditions—for example, in type A insulin resistance syndrome, the ratio becomes markedly elevated due to impaired insulin clearance 2.
Different Measurement Units
The measurements use incompatible units that cannot be directly compared:
- Insulin: Measured in mIU/L or pmol/L
- C-peptide: Measured in ng/mL or pmol/L (with conversion: pmol/L × 0.003 = ng/mL) 1
Even when both are expressed in pmol/L, the actual numerical values differ substantially due to the physiological factors described above.
Clinical Correlation Between the Two
Despite not having the same values, there is a strong positive correlation between fasting C-peptide and fasting insulin levels:
A large cross-sectional study of 48,008 adults found a correlation coefficient of r=0.82 between fasting C-peptide and fasting insulin, with a power function relationship (R²=0.74): FINS = 2.96 × FCP^1.32 3. This demonstrates that while the values differ, they track together in a predictable mathematical relationship.
Diagnostic Implications
Why C-Peptide is Often Preferred
C-peptide has superior diagnostic value compared to insulin for several clinical applications 1:
- More stable measurement: Not affected by exogenous insulin administration
- Better reflects endogenous insulin secretion: Avoids interference from insulin antibodies or cross-reactivity with insulin analogs
- Higher sensitivity and specificity: For diagnosing conditions like insulinoma, C-peptide ≥0.6 ng/mL at glucose ≤0.45 g/L (2.5 mmol/L) has nearly 100% sensitivity and specificity 1
When Each Test is Used
For hypoglycemia evaluation 4:
- Insulin ≥3 µU/mL (18 pmol/L) with glucose <55 mg/dL suggests endogenous hyperinsulinism
- C-peptide ≥0.6 ng/mL (0.2 nmol/L) with the same glucose threshold confirms inappropriate insulin secretion
- Both should be measured simultaneously during documented hypoglycemia
For diabetes classification 5, 6:
- Random C-peptide >600 pmol/L (>1.8 ng/mL) suggests type 2 diabetes
- C-peptide <200 pmol/L (<0.6 ng/mL) indicates severe insulin deficiency (type 1 diabetes)
- Insulin measurements are not routinely recommended for diabetes classification 7
Important Caveats
Ethnic Variations
Significant ethnic differences exist in the C-peptide/insulin relationship:
- African Americans show higher fasting insulin but lower fasting C-peptide compared to whites and Mexican Americans, suggesting altered insulin clearance 8
- The C-peptide/insulin molar ratio is substantially lower in Black individuals 8
Assay Standardization Issues
A critical limitation: C-peptide assays are not yet standardized across manufacturers, leading to significant inter-assay variability 9. This means:
- Cut-off values from guidelines may not apply universally to all laboratory assays
- Results from different laboratories may not be directly comparable
- Clinical decisions based on specific thresholds should account for local assay characteristics
Conditions Affecting the Relationship
The C-peptide/insulin relationship becomes distorted in:
- Renal insufficiency: C-peptide clearance is impaired, elevating levels disproportionately 1
- Hepatic insufficiency: May alter insulin clearance 1
- Insulin resistance syndromes: The C-peptide/insulin molar ratio can increase dramatically (e.g., type A insulin resistance syndrome) 2
Bottom Line
Fasting C-peptide and fasting insulin are complementary but distinct measurements that will never show the same values. They are related through a power function rather than a linear 1:1 relationship, with C-peptide typically present at higher molar concentrations due to differential hepatic clearance. For most clinical purposes, C-peptide is the preferred biomarker due to its stability and lack of interference from exogenous insulin, though both may be measured simultaneously in specific diagnostic scenarios like hypoglycemia evaluation 4.